Poseida Therapeutics, Inc. (PSTX)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Poseida Therapeutics, Inc. ("Poseida" or the "Company") (NASDAQ: PSTX).  The investigation concerns whether Poseida and certain of its officers and/or directors have violated federal securities laws.


On or around July 10, 2020, Poseida completed its initial public offering (“IPO”), issuing 14 million shares of common stock priced at $16.00 per share.  Then, on August 18, 2020, Poseida disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on Poseida’s Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.  The FDA placed the hold in order to investigate a patient death that occurred in late July.  On this news, Poseida’s stock price fell $3.94 per share, or 30.31%, to close at $9.06 per share on August 18, 2020.


If you are aware of any facts relating to this investigation, or purchased Poseida shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.